Gene · 2852
Papers4,367
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,161 to 1,180 of 4,367
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Changes in expression of signal transduction-related genes, and formation of aggregates of GPER1 and OXTR receptors in mucopolysaccharidosis cells. | Eur J Cell Biol | 2022 | 35537249 | PubTator, text mining | PubMed |
| p57Kip2 imposes the reserve stem cell state of gastric chief cells. | Cell Stem Cell | 2022 | 35523142 | PubTator, text mining | PubMed |
| Label-free detection of breast cancer cells using a functionalized tilted fiber grating. | Biomed Opt Express | 2022 | 35519261 | PubTator, text mining | PubMed |
| Biological roles and clinical significance of estrogen and androgen receptors in head and neck cancers. | J Cancer | 2022 | 35517428 | PubTator, text mining | PubMed |
| Angioregulatory microRNAs in breast cancer: Molecular mechanistic basis and implications for therapeutic strategies. | J Adv Res | 2022 | 35499045 | PubTator, text mining | PubMed |
| Endothelial Cullin3 Mutation Impairs Nitric Oxide-Mediated Vasodilation and Promotes Salt-Induced Hypertension. | Function (Oxf) | 2022 | 35493997 | PubTator, text mining | PubMed |
| Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures. | Cancer Cell Int | 2022 | 35488263 | PubTator, text mining | PubMed |
| Functional network analysis of p85 and PI3K as potential gene targets and mechanism of oleanolic acid in overcoming breast cancer resistance to tamoxifen. | J Genet Eng Biotechnol | 2022 | 35482141 | PubTator, text mining | PubMed |
| Cancer-associated fibroblasts in breast cancer: Challenges and opportunities. | Cancer Commun (Lond) | 2022 | 35481621 | PubTator, text mining | PubMed |
| 2',3',4'-Trihydroxychalcone changes estrogen receptor α regulation of genes and breast cancer cell proliferation by a reprogramming mechanism. | Mol Med | 2022 | 35468719 | PubTator, text mining | PubMed |
| Membrane Hormone Receptors and Their Signaling Pathways as Targets for Endocrine Disruptors. | J Xenobiot | 2022 | 35466213 | PubTator, text mining | PubMed |
| Exploration of Reduced Mitochondrial Content-Associated Gene Signature and Immunocyte Infiltration in Colon Adenocarcinoma by an Integrated Bioinformatic Analysis. | Front Genet | 2022 | 35464857 | PubTator, text mining | PubMed |
| Atherogenesis, Transcytosis, and the Transmural Cholesterol Flux: A Critical Review. | Oxid Med Cell Longev | 2022 | 35464770 | PubTator, text mining | PubMed |
| Prediction and Identification of GPCRs Targeting for Drug Repurposing in Osteosarcoma. | Front Oncol | 2022 | 35463319 | PubTator, text mining | PubMed |
| Chemerin enhances mesenchymal features of glioblastoma by establishing autocrine and paracrine networks in a CMKLR1-dependent manner. | Oncogene | 2022 | 35459783 | PubTator, text mining | PubMed |
| CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells. | Mol Cancer | 2022 | 35459184 | PubTator, text mining | PubMed |
| Anti-SARS-CoV-2 potential of Cissampelos pareira L. identified by connectivity map-based analysis and in vitro studies. | BMC Complement Med Ther | 2022 | 35459166 | PubTator, text mining | PubMed |
| Pharmacogenetics of Osteoporosis: A Pathway Analysis of the Genetic Influence on the Effects of Antiresorptive Drugs. | Pharmaceutics | 2022 | 35456610 | PubTator, text mining | PubMed |
| Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go? | Pharmaceutics | 2022 | 35456556 | PubTator, text mining | PubMed |
| Role of Estrogens in Menstrual Migraine. | Cells | 2022 | 35456034 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2852/papers?page=59